Sagimet Advances MASH Combination Therapy With Phase 1 PK Data
SAN MATEO, Calif., Dec. 18, 2025 — Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company focused on metabolic and fibrotic...
MASH
Advertisement
Morphocell Secures $50M to Advance Stem-Cell Liver Therapy
Laval, Québec, December 1, 2025 — Morphocell Technologies has announced the successful completion of its US$50 million Series A...
Can-Fite Highlights Major Progress Across Late-Stage Drug Pipeline
Ramat Gan, Israel, November 26, 2025 — Can-Fite BioPharma has announced key updates across its advanced-stage clinical pipeline ahead...
Tangram Advances TGM-312 With Phase 1/2 CTA Submission
LONDON — November 26, 2025. Tangram Therapeutics has submitted a Clinical Trial Application (CTA) to the UK Medicines and...
PDS Biotechnology Presents Strong Immunotherapy and Translational Data Demonstrating Broad Immune Activation at SITC 2025
Princeton, New Jersey, November 10, 2025 — PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company developing next-generation immunotherapies for cancer...
Advertisements
Gyre Therapeutics Advances Fibrosis-First Pipeline with Strong Q3 Growth and Regulatory Momentum
Dateline — San Diego, California, November 7, 2025:Gyre Therapeutics, Inc. (NASDAQ: GYRE) reported Q3 2025 financial results and a...
Rivus Pharmaceuticals Reports Positive Phase 2 Results for HU6 in MASH Patients
CHARLOTTESVILLE, Va., and SOUTH SAN FRANCISCO, Calif., November 7, 2025 — Rivus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company pioneering...
Roche Completes Acquisition of 89bio in Strategic Biotech Expansion
Basel, Switzerland – October 30, 2025 — Roche Holding AG (SIX: RO, ROG; OTCQX: RHHBY) has successfully completed its...
Sagimet Begins Phase 1 Trial of Denifanstat-Resmetirom Combo in MASH
SAN MATEO, Calif., Oct. 1, 2025 — Sagimet Biosciences announced that it has dosed the first participants in a...
Advertisement
